Drugs / Anti-PD-L1 CSR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02937844 | Jul 2016 → Jul 2018 | glioblastoma | Beijing Sanbo Brain Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-PD-L1 CSR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02937844 ↗ |
| Action | Deplete | “CSR modified T cells are able to recognize PD-L1-expressing tumor cells and transduce signals to activate T cells, which results in tumor killing.” NCT02937844 ↗ |
| Modality | Cell therapy | “CSR modified T cells are able to recognize PD-L1-expressing tumor cells and transduce signals to activate T cells” NCT02937844 ↗ |
| Route | Intravenous | “infused intravenously” NCT02937844 ↗ |